{"id":11502,"date":"2023-06-26T19:04:01","date_gmt":"2023-06-26T16:04:01","guid":{"rendered":"https:\/\/stage.www.cobalt.legal\/?p=11502"},"modified":"2023-06-26T19:04:47","modified_gmt":"2023-06-26T16:04:47","slug":"cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics","status":"publish","type":"post","link":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/","title":{"rendered":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c"},"content":{"rendered":"<p><strong>COBALT atstovavo rizikos kapitalo fond\u0105 \u201ePractica Capital\u201c kartu su verslo angelais investuojant\u00a0 <\/strong><strong>1 mln. Eur<\/strong><strong> \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f <\/strong><strong>\u201eDroplet Genomics\u201c<\/strong><strong>. Investicija suteikia startuoliui galimybes prapl\u0117sti intelektin\u0117s nuosavyb\u0117s portfel\u012f bei paspartinti nauj\u0173 produkt\u0173 komercializavim\u0105.<\/strong><\/p>\n<p>\u201eDroplet Genomics\u201d yra Lietuvoje \u012fkurta ir veikianti biotechnologij\u0173 \u012fmon\u0117, komercializuojanti la\u0161eli\u0173 mikroskys\u010di\u0173 technologij\u0105. D4l itin auk\u0161to analiz\u0117s na\u0161umo ir skiriamos gebos, \u0161i technologija \u012fgalina mokslininkus atlikti pavieni\u0173 l\u0105steli\u0173 ir pavieni\u0173 molekuli\u0173 tyrimus, kurie leid\u017eia detaliau pa\u017einti sud\u0117tingas biologines sistemas bei atveria nauj\u0173 atradim\u0173 galimybes tiriant \u017emogaus lig\u0173 mechanizmus. Startuolis kuria mokslini\u0173 tyrim\u0173 prietaisus, reagentus bei programin\u0119 \u012frang\u0105, siekdamas rinkai pasi\u016blyti inovatyvius ir lengvai pritaikomus sprendimus, kurie pad\u0117t\u0173 efektyviau ir grei\u010diau atlikti sud\u0117ting\u0173 biologini\u0173 sistem\u0173 bei vaist\u0173 k\u016brimo tyrimus.<\/p>\n<p>\u201eDroplet Genomics\u201c aktyviai dirba ties nauj\u0173 produkt\u0173 k\u016brimu ir planuoja jau \u0161iemet pasi\u016blyti integruot\u0105 platform\u0105 auk\u0161to na\u0161umo analiz\u0117s tyrimams, kuri papildys \u012fmon\u0117s jau si\u016blom\u0105 lengvo naudojimo inovatyvi\u0105 la\u0161eli\u0173 mikroskys\u010di\u0173 tyrim\u0173 platform\u0105. \u012emon\u0117s pagrindiniai klientai yra \u0160iaur\u0117s Amerikos ir Europos universitetai, mokslo tyrim\u0173 institutai, biotechnologij\u0173 pramon\u0117s \u012fmon\u0117s.<\/p>\n<p>\u201eKomandos ilgalaik\u0117 vizija yra itin ambicinga, siekianti \u012fgalinti personalizuot\u0105 medicin\u0105. Tai yra pasaulinio lygio u\u017edaviniai.\u00a0 \u017dinome, kad \u201eDroplet Genomics\u201d reik\u0117s daugiau laiko pasiekti u\u017esibr\u0117\u017et\u0173 tiksl\u0173, tod\u0117l m\u016bs\u0173 u\u017edavinys ne tik i\u0161likti kantriems, bet ir pad\u0117ti darant pirmuosius \u017eingsnius, pritraukiant papildomas kompetencijas bei jau dabar prad\u0117ti dirbti su regioniniais ir pasauliniais rizikos kapitalo partneriais, siekiant u\u017etikrinti savalaik\u012f ir pakankam\u0105 finansavim\u0105 tolimesniuose \u012fmon\u0117s vystymosi etapuose. Labai vertiname Juozo, Lino ir likusios komandos pasitik\u0117jim\u0105 mumis ir pasiekt\u0105 partneryst\u0119\u201d, \u2013 pasakojo Donatas Keras, \u201ePractica Capital\u201c partneris.<\/p>\n<p>COBALT konsultavo sandorio strukt\u016bros klausimais, reng\u0117 sandorio dokumentus, atstovavo \u201ePractica Capital\u201c derybose, atliko teisin\u012f patikrinim\u0105 ir konsultavo kitais su sandoriu susijusiais klausimais. Projekto komandoje \u2013 partner\u0117, bankininkyst\u0117s ir finans\u0173 praktikos grup\u0117s vadov\u0117 Eva Suduiko bei vyresnioji teisinink\u0117 Aurelija Bal\u010di\u016bn\u0117.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>COBALT atstovavo rizikos kapitalo fond\u0105 \u201ePractica Capital\u201c kartu su verslo angelais investuojant\u00a0 1 mln. Eur \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c. Investicija suteikia startuoliui galimybes prapl\u0117sti intelektin\u0117s nuosavyb\u0117s portfel\u012f bei paspartinti nauj\u0173 produkt\u0173 komercializavim\u0105. \u201eDroplet Genomics\u201d yra Lietuvoje \u012fkurta ir..<\/p>\n","protected":false},"author":5,"featured_media":11507,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[29],"country":[92],"class_list":["post-11502","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-lt","country-lithuania-lt"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c | COBALT<\/title>\n<meta name=\"description\" content=\"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c. News. Naujienos. Jaunumi. Uudised.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/\" \/>\n<meta property=\"og:locale\" content=\"lt_LT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c | COBALT\" \/>\n<meta property=\"og:description\" content=\"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c. News. Naujienos. Jaunumi. Uudised.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/\" \/>\n<meta property=\"og:site_name\" content=\"COBALT\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CobaltLegal\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-26T16:04:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-26T16:04:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/06\/bloodpressure3524615_19204424.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1050\" \/>\n\t<meta property=\"og:image:height\" content=\"668\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"saturs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"saturs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minut\u0117s\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/\"},\"author\":{\"name\":\"saturs\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/person\\\/8b9371cd6186321c5b42e891663a4ec0\"},\"headline\":\"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c\",\"datePublished\":\"2023-06-26T16:04:01+00:00\",\"dateModified\":\"2023-06-26T16:04:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/\"},\"wordCount\":334,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/bloodpressure3524615_19204424.jpg\",\"articleSection\":[\"Uncategorized @lt\"],\"inLanguage\":\"lt-LT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/\",\"name\":\"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c | COBALT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/bloodpressure3524615_19204424.jpg\",\"datePublished\":\"2023-06-26T16:04:01+00:00\",\"dateModified\":\"2023-06-26T16:04:47+00:00\",\"description\":\"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c. News. Naujienos. Jaunumi. Uudised.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/#breadcrumb\"},\"inLanguage\":\"lt-LT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/bloodpressure3524615_19204424.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/bloodpressure3524615_19204424.jpg\",\"width\":1050,\"height\":668},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#website\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/\",\"name\":\"COBALT\",\"description\":\"Top-tier law services in Estonia, Latvia and Lithuania\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"lt-LT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#organization\",\"name\":\"COBALT\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/cobalt-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/cobalt-logo.png\",\"width\":400,\"height\":116,\"caption\":\"COBALT\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/CobaltLegal\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/person\\\/8b9371cd6186321c5b42e891663a4ec0\",\"name\":\"saturs\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/author\\\/saturs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c | COBALT","description":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c. News. Naujienos. Jaunumi. Uudised.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/","og_locale":"lt_LT","og_type":"article","og_title":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c | COBALT","og_description":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c. News. Naujienos. Jaunumi. Uudised.","og_url":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/","og_site_name":"COBALT","article_publisher":"https:\/\/www.facebook.com\/CobaltLegal\/","article_published_time":"2023-06-26T16:04:01+00:00","article_modified_time":"2023-06-26T16:04:47+00:00","og_image":[{"width":1050,"height":668,"url":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/06\/bloodpressure3524615_19204424.jpg","type":"image\/jpeg"}],"author":"saturs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"saturs","Est. reading time":"2 minut\u0117s"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/#article","isPartOf":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/"},"author":{"name":"saturs","@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/person\/8b9371cd6186321c5b42e891663a4ec0"},"headline":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c","datePublished":"2023-06-26T16:04:01+00:00","dateModified":"2023-06-26T16:04:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/"},"wordCount":334,"publisher":{"@id":"https:\/\/www.cobalt.legal\/lt\/#organization"},"image":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/06\/bloodpressure3524615_19204424.jpg","articleSection":["Uncategorized @lt"],"inLanguage":"lt-LT"},{"@type":"WebPage","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/","url":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/","name":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c | COBALT","isPartOf":{"@id":"https:\/\/www.cobalt.legal\/lt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/#primaryimage"},"image":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/06\/bloodpressure3524615_19204424.jpg","datePublished":"2023-06-26T16:04:01+00:00","dateModified":"2023-06-26T16:04:47+00:00","description":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c. News. Naujienos. Jaunumi. Uudised.","breadcrumb":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/#breadcrumb"},"inLanguage":"lt-LT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/"]}]},{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/#primaryimage","url":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/06\/bloodpressure3524615_19204424.jpg","contentUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/06\/bloodpressure3524615_19204424.jpg","width":1050,"height":668},{"@type":"BreadcrumbList","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/cobalt-atstovavo-practica-capital-investuojant-i-lietuviu-biotechnologiju-startuoli-droplet-genomics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cobalt.legal\/lt\/"},{"@type":"ListItem","position":2,"name":"COBALT atstovavo \u201ePractica Capital\u201c investuojant \u012f lietuvi\u0173 biotechnologij\u0173 startuol\u012f \u201eDroplet Genomics\u201c"}]},{"@type":"WebSite","@id":"https:\/\/www.cobalt.legal\/lt\/#website","url":"https:\/\/www.cobalt.legal\/lt\/","name":"COBALT","description":"Top-tier law services in Estonia, Latvia and Lithuania","publisher":{"@id":"https:\/\/www.cobalt.legal\/lt\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cobalt.legal\/lt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"lt-LT"},{"@type":"Organization","@id":"https:\/\/www.cobalt.legal\/lt\/#organization","name":"COBALT","url":"https:\/\/www.cobalt.legal\/lt\/","logo":{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/logo\/image\/","url":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/04\/cobalt-logo.png","contentUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/04\/cobalt-logo.png","width":400,"height":116,"caption":"COBALT"},"image":{"@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CobaltLegal\/"]},{"@type":"Person","@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/person\/8b9371cd6186321c5b42e891663a4ec0","name":"saturs","url":"https:\/\/www.cobalt.legal\/lt\/author\/saturs\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts\/11502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/comments?post=11502"}],"version-history":[{"count":1,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts\/11502\/revisions"}],"predecessor-version":[{"id":11503,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts\/11502\/revisions\/11503"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/media\/11507"}],"wp:attachment":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/media?parent=11502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/categories?post=11502"},{"taxonomy":"country","embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/country?post=11502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}